Solid Malignant Tumor Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting solid malignant tumor clinical trials across 8 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Nashville, Tennessee, United States, Detroit, Michigan, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Solid Malignant Tumor Trials at a Glance

8 actively recruiting trials for solid malignant tumor are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Nashville, Detroit, and Atlanta. Lead sponsors running solid malignant tumor studies include Dan Zandberg, Mayo Clinic, and Chipscreen Biosciences, Ltd..

Browse solid malignant tumor trials by phase

Treatments under study

About Solid Malignant Tumor Clinical Trials

Looking for clinical trials for Solid Malignant Tumor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Malignant Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Malignant Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Not Applicable

High-Resolution PET-CT Imaging for Surgical Margin Visualization

CancerHNSCCSCC - Squamous Cell Carcinoma+2 more
Vanderbilt-Ingram Cancer Center50 enrolled1 locationNCT06915454
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1Phase 2

Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors

Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
Shenzhen University General Hospital20 enrolled1 locationNCT07399769
Recruiting

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

Hematologic MalignancyMyocarditisSubclinical Immune Checkpoint Inhibitor-Induced Myocarditis+4 more
Mayo Clinic30 enrolled1 locationNCT06566209
Recruiting
Phase 1Phase 2

A Beta-only IL-2 ImmunoTherapY Study

Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 1Phase 2

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Small Cell Lung CancerAdvanced Solid Malignant Tumor
Chipscreen Biosciences, Ltd.36 enrolled11 locationsNCT05271292
Recruiting
Phase 2

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech108 enrolled33 locationsNCT03941574